US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Report on Operations 2019: High Time-lapse growth

    Fourth quarter · Sales amounted to SEK 409 (320) million, corresponding to an increase of 28 percent in SEK. Sales increased by 21 percent in local currency whereof 11 percent comprised organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 160 (135) million, corresponding to a margin of 39 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million. · Net income amounted to SEK 96 (84) million, which gave earnings per share of SEK 0.89 (0.77). Whole year 2019 · Sales amounted to SEK 1 480 (1 151)

    Interim report January – September 2019: Continued profitable growth

    Third quarter: · Sales amounted to SEK 378 (284) million, corresponding to an increase of 33 percent in SEK. Sales increased by 27 percent in local currency whereof 15 percent comprised organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 155 (121) million, corresponding to a margin of 41 (43) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 9 million. · Net income amounted to SEK 107 (75) million, which gave earnings per share of SEK 0.98 (0.69). January - September: · Sales amounted to SEK 1 071 (831)

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January – September 2019. The presentation will be held in English.Time: Wednesday 6 November, 2019 at 10.00 a.m. CET. Registration can preferably be done 10 minutes before the conference start time on: Sweden dial in number: +46 (0)8 506 921 69  International dial in number: +44 (0) 203 0095709  Conference name: Vitrolife, conference ID: 6995418 Vitrolife participants:Thomas Axelsson, CEO Mikael Engblom, CFOThe press release for Vitrolife’s interim report will

    Election committee for Vitrolife AB (publ)

    The following people have been appointed as members of Vitrolife’s election committee for the Annual General Meeting in 2020:Niels Jacobsen, representing William Demant Invest A/SPatrik Tigerschiöld, representing Bure Equity ABWendy Wang, representing Morgan Stanley Investment Management Inc.Jón Sigurdsson, Chairman of the BoardThe appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on May 2, 2019. The Annual General Meeting of

    Collaboration agreement on Piezo technique for improved ICSI procedure

    Vitrolife has entered into a collaboration agreement with Prime Tech to develop and exclusively market the Piezo technique for improved ICSI procedure in human IVF globally except for Japan, Thailand and Malaysia. Vitrolife will as part of the agreement initiate regulatory approval initiatives in various markets to enable future commercialization of the technology.Intracytoplasmic Sperm Injection (ICSI) is a specialised form of In Vitro Fertilisation (IVF) that is used primarily for the treatment of male-factor infertility. ICSI involves the injection of a single sperm directly into a

    Interim report January – June 2019: High growth and good profitability

    Second quarter: · Sales amounted to SEK 381 (283) million, corresponding to an increase of 34 percent in SEK. Sales increased by 29 percent in local currency whereof 18 percent comprised organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 146 (116) million, corresponding to a margin of 38 (41) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million. · Net income amounted to SEK 95 (80) million, which gave earnings per share of SEK 0.87 (0.73). · Acquisition and collaboration agreement regarding technology

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January – June 2019. The presentation will be held in English.Time: Friday July 12, 2019 at 10.00 a.m. CET. Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +46 (0)8 506 921 69  International dial in number: +44 (0) 203 0095709  Conference name: Vitrolife, conference ID: 3736488 Vitrolife participants:Thomas Axelsson, CEO Mikael Engblom, CFOThe press release for Vitrolife’s interim report will be

    Vitrolife acquires the business of UK distributor Parallabs

    Vitrolife has today acquired the business of Parallabs Ltd, its distributor in UK and Ireland for EmbryoScope time-lapse systems, and thereby strengthens its presence in UK and Ireland.Parallabs Ltd has been the Vitrolife UK and Ireland distributor for EmbryoScope time-lapse systems since 2011 and has achieved a high penetration for time-lapse in the market. “The acquisition strengthens Vitrolife in the UK and Ireland by getting access to a wealth of experience from Parallabs, as well as being able to offer customers the complete Vitrolife portfolio from a single sales channel”; says Thomas

    Report from Annual General Meeting of Vitrolife AB (publ)

    At Vitrolife’s Annual General Meeting today, the following, amongst other things, was decided: · The Board’s proposed dividend of SEK 0.85 per share for the financial year 2018 was approved. Monday May 6, 2019 was adopted as the record day.  · Re-election of Board members Barbro Fridén, Lars Holmqvist, Pia Marions and Jón Sigurdsson and new election of Henrik Blomquist, in accordance with the election committee’s proposal. Jón Sigurdsson was elected Chairman of the Board (new election). · Remuneration to the members of the Board shall be totalling SEK 2,165,000, of which SEK

    Vitrolife has received order for 20 EmbryoScope+ to leading clinic in China

    In March, Vitrolife AB (publ) received market approval for the time-lapse incubator EmbryoScope+ in China. The company has now received order for 20 EmbryoScope+ to be installed at a leading clinic in China during the second quarter. The order is the largest single order for EmbryoScope+ so far for Vitrolife.EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In March, Vitrolife received market

    Interim report January – March 2019: High profitability and new business unit

    First quarter:· Sales amounted to SEK 312 (264) million, corresponding to an increase of 18 percent in SEK. Sales increased by 12 percent in local currency whereof 4 percent comprised organic growth.· Operating income before depreciation and amortisation (EBITDA) amounted to SEK 126 (106) million, corresponding to a margin of 40 (40) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 14 million.· Net income amounted to SEK 86 (72) million, which gave earnings per share of SEK 0.79 (0.66).· Market approval for EmbryoScope+ in China. After the end of the

    Vitrolife acquires artificial intelligence technology for embryo assessment

    Vitrolife has acquired rights to a technology for assessing embryos based on time-lapse videos using artificial intelligence (“AI”) and entered into collaboration agreements to further develop the technology.Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia. Using time-lapse videos during in vitro fertilisation (IVF), and before embryo

    Notice of Annual General Meeting of Vitrolife AB (publ)

    The Annual General Meeting of Vitrolife AB (publ) will take place on Thursday May 2, 2019, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Thursday, April 25, 2019.Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83 or by e-mail investors@vitrolife.com. Full name/business name, preferably personal identification number/ company

    EmbryoScope+ approved for sales in China

    Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in China, the world's largest market measured in terms of number of IVF treatments.EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In 2018, Vitrolife received market approval in China for the EmbryoScope time-lapse system, with capacity for six patients. "We are delighted to receive market approval

    Information from Vitrolife´s Election Committee

    Board member Jón Sigurdsson is proposed as new Chairman of the Board of Vitrolife AB (publ).The Election Committee proposes the following for the Annual General Meeting of Vitrolife on Thursday, 2 May 2019: - that the Board shall consist of five Board members. - re-election of Board members Barbro Fridén, Lars Holmqvist, Pia Marions and Jón Sigurdsson and election of the new Board member Henrik Blomquist, CEO Bure Equity AB. Carsten Browall has declined re-election. - Election of Jón Sigurdsson as Chairman of the Board, member of Vitrolife's Board since 2015. “Carsten Browall

    Conference call Report on Operations 2018

    Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2018. The presentation will be held in English.Time: Friday 8 February, 2019 at 10.00 a.m. CET. Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +46 (0)8 506 921 69  International dial in number: +44 (0) 203 0095709  Conference name: Vitrolife, conference ID: 4469227 Vitrolife participants:Thomas Axelsson, CEO Mikael Engblom, CFOThe press release for Vitrolife’s Report on Operations will be released at 8.30 CET

    Capital Markets Day highlights

    At the Vitrolife Capital Markets Day this evening, the company provided an update of the market trends and strategy together with a presentation of the new genomics partnership with Illumina. Furthermore, the history and future of IVF was presented.The Capital Markets Day was held at the company’s premises in Göteborg with approximately 45 participants. The CEO Thomas Axelsson presented the financial and operational performance during the year and the trends that can be seen in the market including clinic consolidation and increased demand for technologies such as time-lapse,

    Interim report January – September 2018: High profitability and strengthened offer

    Third quarter: · Sales amounted to SEK 284 (246) million, corresponding to an increase of 15 percent in SEK. Sales increased by 7 percent in local currency and consisted of organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 121 (98) million, corresponding to a margin of 43 (40) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 11 million. · Net income amounted to SEK 75 (65) million, which gave earnings per share of SEK 0.69 (0.60). January-September: · Sales amounted to SEK 831 (775) million,

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January – September 2018. The presentation will be held in English.Time: Tuesday 6 November, 2018 at 10.00 a.m. CET. Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +46 (0)8 506 921 69  International dial in number: +44 (0) 203 0095709  Conference name: Vitrolife, conference ID: 1938678 Vitrolife participants:Thomas Axelsson, CEO Mikael Engblom, CFOThe press release for Vitrolife’s interim report will

    Election committee for Vitrolife AB (publ)

    The following people have been appointed as members of Vitrolife’s election committee for the Annual General Meeting in 2019: Niels Jacobsen, representing William Demant Invest A/SPatrik Tigerschiöld, representing Bure Equity ABJohan Ståhl, representing Lannebo FonderCarsten Browall, Chairman of the BoardThe appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on April 26, 2018.The Annual General Meeting of Vitrolife AB (publ)

    Invitation to Capital Markets Day on November 21

    Vitrolife AB (publ) hereby invites analysts, investors, shareholders and journalists to a Capital Markets Day on November 21.We will talk about Vitrolife’s business, which assists in making many people’s desire to have children a reality. We will give an update on the market trends and the strategy together with an update on the operative and financial development. Furthermore, we will present the new partnership with Illumina on preimplantation genetic testing. There will be an opportunity to visit one of our production facilities between approx. 15:30-16:30. The presentations will be held

    Vitrolife partners with Illumina on preimplantation genetic testing

    Vitrolife AB (publ) has entered into a License and Commercialisation Agreement with Illumina, Inc., which provides Vitrolife with exclusive distribution, development and commercialisation rights to Illumina’s preimplantation genetic testing business for IVF in EMEA and Americas.Beginning in early 2019, Vitrolife will be the exclusive distributor of Illumina’s preimplantation genetic testing for aneuploidy (PGT-A) kit VeriSeq™ PGS and preimplantation genetic testing for monogenic and single gene defects (PGT-M) kit HumanKaryomap-12 in EMEA (Europe, Middle East and Africa) and Americas. In

    Interim report January – June 2018: Continued high profitability

    Second quarter: · Sales amounted to SEK 283 (285) million, corresponding to a decrease of 1 percent in SEK. Sales decreased by 5 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 116 (112) million, corresponding to a margin of 41 (39) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 8 million. · Net income amounted to SEK 80 (71) million, which gave earnings per share of SEK 0.73 (0.66). · Market approval for EmbryoScope+ in the US. · Share split 5:1 carried out in line with the resolution

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe